Sagimet Biosciences (SGMT) Competitors $3.41 +0.19 (+5.90%) Closing price 04:00 PM EasternExtended Trading$3.41 0.00 (0.00%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SGMT vs. ABVX, TRML, PGEN, RGNX, MREO, ERAS, KMDA, VERV, TECX, and ORICShould you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include ABIVAX Société Anonyme (ABVX), Tourmaline Bio (TRML), Precigen (PGEN), REGENXBIO (RGNX), Mereo BioPharma Group (MREO), Erasca (ERAS), Kamada (KMDA), Verve Therapeutics (VERV), Tectonic Therapeutic (TECX), and ORIC Pharmaceuticals (ORIC). These companies are all part of the "pharmaceutical products" industry. Sagimet Biosciences vs. ABIVAX Société Anonyme Tourmaline Bio Precigen REGENXBIO Mereo BioPharma Group Erasca Kamada Verve Therapeutics Tectonic Therapeutic ORIC Pharmaceuticals Sagimet Biosciences (NASDAQ:SGMT) and ABIVAX Société Anonyme (NASDAQ:ABVX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, community ranking, risk and profitability. Which has higher valuation & earnings, SGMT or ABVX? Sagimet Biosciences has higher revenue and earnings than ABIVAX Société Anonyme. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSagimet Biosciences$2M52.30-$27.88M-$1.76-1.94ABIVAX Société AnonymeN/AN/A-$159.90MN/AN/A Is SGMT or ABVX more profitable? ABIVAX Société Anonyme's return on equity of 0.00% beat Sagimet Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Sagimet BiosciencesN/A -23.63% -22.91% ABIVAX Société Anonyme N/A N/A N/A Do institutionals and insiders believe in SGMT or ABVX? 87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 47.9% of ABIVAX Société Anonyme shares are owned by institutional investors. 14.7% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor SGMT or ABVX? Sagimet Biosciences received 17 more outperform votes than ABIVAX Société Anonyme when rated by MarketBeat users. Likewise, 96.43% of users gave Sagimet Biosciences an outperform vote while only 76.92% of users gave ABIVAX Société Anonyme an outperform vote. CompanyUnderperformOutperformSagimet BiosciencesOutperform Votes2796.43% Underperform Votes13.57%ABIVAX Société AnonymeOutperform Votes1076.92% Underperform Votes323.08% Does the media favor SGMT or ABVX? In the previous week, Sagimet Biosciences had 1 more articles in the media than ABIVAX Société Anonyme. MarketBeat recorded 3 mentions for Sagimet Biosciences and 2 mentions for ABIVAX Société Anonyme. ABIVAX Société Anonyme's average media sentiment score of 0.87 beat Sagimet Biosciences' score of 0.00 indicating that ABIVAX Société Anonyme is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ABIVAX Société Anonyme 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, SGMT or ABVX? Sagimet Biosciences has a beta of 2.32, meaning that its stock price is 132% more volatile than the S&P 500. Comparatively, ABIVAX Société Anonyme has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500. Do analysts recommend SGMT or ABVX? Sagimet Biosciences presently has a consensus target price of $22.40, indicating a potential upside of 556.89%. ABIVAX Société Anonyme has a consensus target price of $31.00, indicating a potential upside of 412.40%. Given Sagimet Biosciences' higher probable upside, equities analysts plainly believe Sagimet Biosciences is more favorable than ABIVAX Société Anonyme.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sagimet Biosciences 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80ABIVAX Société Anonyme 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummarySagimet Biosciences beats ABIVAX Société Anonyme on 10 of the 15 factors compared between the two stocks. Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SGMT vs. The Competition Export to ExcelMetricSagimet BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$104.60M$6.48B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-1.949.0626.7119.71Price / Sales52.30251.50386.13120.55Price / CashN/A65.8538.2534.62Price / Book0.866.456.774.50Net Income-$27.88M$143.98M$3.23B$248.22M7 Day Performance3.02%2.41%1.80%0.56%1 Month Performance33.73%4.56%11.10%13.17%1 Year Performance-32.87%-2.67%17.11%7.30% Sagimet Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SGMTSagimet Biosciences1.5847 of 5 stars$3.41+5.9%$22.40+556.9%-32.8%$104.60M$2M-1.948ABVXABIVAX Société Anonyme2.4466 of 5 stars$6.40-4.6%$34.00+431.3%-59.3%$405.88MN/A0.0061TRMLTourmaline Bio1.8613 of 5 stars$15.78+4.5%$49.33+212.6%+7.7%$405.31MN/A-5.6044PGENPrecigen3.3849 of 5 stars$1.37+3.0%$7.00+410.9%-5.0%$404.38M$3.93M-2.49190News CoverageAnalyst RevisionHigh Trading VolumeRGNXREGENXBIO4.1975 of 5 stars$7.97+6.0%$31.63+296.8%-37.1%$399.43M$83.33M-1.58370Analyst RevisionMREOMereo BioPharma Group1.9263 of 5 stars$2.50+3.7%$7.71+208.6%-26.3%$397.50M$1M-41.6740Positive NewsGap UpERASErasca3.5938 of 5 stars$1.39flat$4.83+247.7%-48.1%$393.77MN/A-1.67120Positive NewsKMDAKamada3.9227 of 5 stars$6.82-0.9%$14.67+115.1%+28.9%$392.01M$160.95M24.36360Analyst UpgradeAnalyst RevisionVERVVerve Therapeutics3.513 of 5 stars$4.35+2.8%$25.75+492.0%-23.6%$387.77M$32.33M-1.77110Trending NewsAnalyst UpgradeAnalyst RevisionTECXTectonic Therapeutic3.596 of 5 stars$20.71+4.8%$72.40+249.6%N/A$386.68MN/A-3.52120ORICORIC Pharmaceuticals4.4264 of 5 stars$5.41+6.5%$19.17+254.3%-34.0%$384.59MN/A-2.9780Positive News Related Companies and Tools Related Companies ABIVAX Société Anonyme Competitors Tourmaline Bio Competitors Precigen Competitors REGENXBIO Competitors Mereo BioPharma Group Competitors Erasca Competitors Kamada Competitors Verve Therapeutics Competitors Tectonic Therapeutic Competitors ORIC Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SGMT) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sagimet Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
